Audentes Therapeutics (NASDAQ:BOLD) Given a $37.00 Price Target by HC Wainwright Analysts

Audentes Therapeutics (NASDAQ:BOLD) has been assigned a $37.00 price target by equities researchers at HC Wainwright in a research note issued on Thursday, January 4th. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 2.29% from the stock’s previous close.

A number of other research analysts have also recently issued reports on BOLD. Bank of America reissued a “buy” rating and issued a $33.00 target price (up from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. Zacks Investment Research cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Raymond James Financial initiated coverage on Audentes Therapeutics in a research note on Thursday, October 12th. They issued a “market perform” rating for the company. ValuEngine cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, October 13th. Finally, William Blair initiated coverage on Audentes Therapeutics in a research report on Tuesday, October 17th. They set an “outperform” rating and a $35.00 price objective for the company. Two analysts have rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $35.00.

Audentes Therapeutics (NASDAQ BOLD) traded up $2.52 during midday trading on Thursday, reaching $36.17. The company had a trading volume of 456,500 shares, compared to its average volume of 711,500. The company has a market capitalization of $1,080.00 and a P/E ratio of -10.39. Audentes Therapeutics has a fifty-two week low of $13.90 and a fifty-two week high of $41.80.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.88) EPS for the quarter, meeting analysts’ consensus estimates of ($0.88). sell-side analysts expect that Audentes Therapeutics will post -3.5 EPS for the current fiscal year.

In related news, SVP Mary Newman sold 10,000 shares of the company’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $26.84, for a total transaction of $268,400.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Louis G. Lange sold 18,000 shares of the company’s stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $30.88, for a total value of $555,840.00. The disclosure for this sale can be found here. Insiders have sold 36,000 shares of company stock worth $1,052,480 in the last quarter. 47.30% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the business. Highbridge Capital Management LLC raised its stake in Audentes Therapeutics by 45.3% in the third quarter. Highbridge Capital Management LLC now owns 60,000 shares of the biotechnology company’s stock valued at $1,681,000 after buying an additional 18,720 shares during the period. Perceptive Advisors LLC raised its stake in Audentes Therapeutics by 10.4% in the third quarter. Perceptive Advisors LLC now owns 781,309 shares of the biotechnology company’s stock valued at $21,885,000 after buying an additional 73,809 shares during the period. Mckinley Capital Management LLC Delaware bought a new stake in Audentes Therapeutics in the third quarter valued at approximately $1,333,000. Wells Fargo & Company MN raised its stake in Audentes Therapeutics by 86.1% in the third quarter. Wells Fargo & Company MN now owns 14,414 shares of the biotechnology company’s stock valued at $404,000 after buying an additional 6,667 shares during the period. Finally, Citadel Advisors LLC raised its stake in Audentes Therapeutics by 981.3% in the third quarter. Citadel Advisors LLC now owns 110,921 shares of the biotechnology company’s stock valued at $3,107,000 after buying an additional 100,663 shares during the period. Hedge funds and other institutional investors own 78.95% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://stocknewstimes.com/2018/01/12/audentes-therapeutics-bold-given-a-37-00-price-target-by-hc-wainwright-analysts.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply